IMRN Stock Summary and Trading Ideas (Immuron Limited - American Depositary Shares | NASDAQ:IMRN)

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Immuron Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol IMRN.

As of October 16, 2026, IMRN stock price declined to $0.98 with 20,713 million shares trading.

IMRN has a beta of 1.50, meaning it tends to be more sensitive to market movements. IMRN has a correlation of 0.03 to the broad based SPY ETF.

IMRN has a market cap of $7.93 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, IMRN traded as high as $5.96 and as low as $.68.

IMRN has underperformed the market in the last year with a price return of -55.4% while the SPY ETF gained +16.7%. IMRN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.1% and -9.9%, respectively, while the SPY returned +1.9% and -0.8%, respectively.

IMRN support price is $.99 and resistance is $1.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMRN shares will trade within this expected range on the day.